Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of December 2008, with the report dated December 15, 2008. The filing serves to incorporate by reference a press release issued on December 12, 2008, regarding a significant legal development.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a legal disclosure rather than a financial statement.
Material Changes
The primary material event reported is a favorable legal ruling. Sanofi-Aventis and its partner Bristol-Myers Squibb prevailed before the U.S. Court of Appeals for the Federal Circuit in a patent infringement case concerning the drug Plavix.
Outlook, Risks, and Management Commentary
The filing highlights a reduction in legal risk regarding the Plavix patent portfolio in the United States. There is no forward-looking financial guidance, management commentary on operational performance, or discussion of other contingencies included in this specific document.
Investor Verification Checklist
- Verify the finality of the U.S. Court of Appeals ruling on the Plavix patent case.
- Assess the potential financial impact of the patent victory on future Plavix revenue streams.
- Review the full text of the press release (Exhibit 99.1) for details on the scope of the court's decision.
- Confirm whether this ruling affects ongoing litigation or settlement discussions with other parties.